Imbruvica® (ibrutinib) – New Indication
January 19, 2017 – AbbVie announced the FDA approval of Imbruvica (ibrutinib) for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
Download PDF
